EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial

Dimitrios Kalyvianakis, Ioannis Mykoniatis, Nikolaos Pyrgidis iD, Paraskeui Kapoteli, Filimon Zilotis, Dimitrios Hatzichristou

The Journal of Sexual Medicine · 28.05.2024 · 21 (6) · 533-538

DOI: 10.1093/jsxmed/qdae038 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Sexual Medicine, online erschienen am 10.04.2024. Verfasst von Dimitrios Kalyvianakis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Aristotle University of Thessaloniki, Thessaloniki 54635, Greece. Hauptthemen laut MEDLINE: Tadalafil, Phosphodiesterase 5 Inhibitors, Erectile Dysfunction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Institute for the Study of Urological Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with severe erectile dysfunction (ED) remain the most challenging group in terms of available noninvasive treatment modalities.

Aim

The study sought to assess the role of combination therapy with low-intensity shockwave therapy (LiST) and daily tadalafil 5 mg in a highly select group of patients with severe vasculogenic ED through a double-blind, randomized trial.

Methods

Forty-eight sexually active men were randomly assigned to 12 sessions of LiST 3 times weekly and tadalafil 5 mg once daily (n = 34) or sham therapy and tadalafil (n = 17) for 4 weeks. Patients were assessed at 1 and 3 months after completion of treatment. Outcomes Improvement of erectile function was evaluated through the International Index of Erectile Function–Erectile Function domain (IIEF-EF) or 6-item IIEF and the Sexual Encounter Profile (SEP) diary. The primary outcome was the difference between the groups in the IIEF-EF at 3 months after completion of treatment. Secondary outcomes comprised (1) the difference between the groups in the IIEF-EF at 1 month after completion of treatment, (2) the difference between the groups in the “yes” responses to question 3 of the SEP diary at 1 and 3 months, and (3) the treatment-related adverse events. The number of patients attaining a minimal clinically important difference in the IIEF-EF (improvement of at least 7 points) was also assessed.

Results

After treatment, the absolute scores in the IIEF-EF were higher in patients receiving LiST and tadalafil vs sham therapy and tadalafil both at the 1-month (12.1 ± 2.4 vs 10.2 ± 1.7; P = .002) and at the 3-month (12.9 ± 2.1 vs 10.8 ± 1.8; P < .001) evaluation. Between the 2 groups, the proportion of “yes” responses to question 3 of the SEP diary was not statistically significant, whereas the number of patients attaining a minimal clinically important difference in the IIEF-EF was statistically significant only at the 3-month evaluation. No adverse events occurred. Clinical Implications Application of LiST in patients with severe vasculogenic ED receiving daily dose tadalafil may further improve erectile function compared with tadalafil as a stand-alone treatment on the short term. Strengths and Limitations Although we provided the first study in the field, severe vasculogenic ED was defined based on medical history and clinical examination and not based on penile ultrasound measures.

Conclusion

The combination of 12 sessions LiST 3 times weekly and daily tadalafil for 4 weeks led to a 2-point difference in the IIEF-EF compared with sham therapy and daily tadalafil among patients with severe vasculogenic ED after 1 and 3 months from completion of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TadalafilPhosphodiesterase 5 InhibitorsErectile DysfunctionHumansMaleDouble-Blind MethodMiddle AgedCombined Modality TherapyExtracorporeal Shockwave TherapyTreatment OutcomeAdultImpotence, VasculogenicSeverity of Illness Index

Stichwörter der Autor:innen

combination therapyerectile dysfunctionerectile functionlow-intensity shockwave therapysham-controlled trialtadalafil

Substanzen

TadalafilPhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Aristotle University of Thessaloniki, Thessaloniki 54635, Greece.
  • Institute for the Study of Urological Diseases, Thessaloniki 54622, Greece.
  • Department of Urology, University Hospital, LMU Munich, Munich 81377, Germany.

ORCID-Profile: Nikolaos Pyrgidis

Förderung

  • Institute for the Study of Urological Diseases

Zitieren

APA

Kalyvianakis, D., Mykoniatis, I., Pyrgidis, N., Kapoteli, P., Zilotis, F., & Hatzichristou, D. (2024). The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. The Journal of Sexual Medicine, 21(6), 533-538. https://doi.org/10.1093/jsxmed/qdae038

Vancouver

Kalyvianakis D, Mykoniatis I, Pyrgidis N, Kapoteli P, Zilotis F, Hatzichristou D. The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. The Journal of Sexual Medicine. 2024;21(6):533-538. doi:10.1093/jsxmed/qdae038

BibTeX
@article{Kalyvianakis2024,
  author = {Kalyvianakis, Dimitrios and Mykoniatis, Ioannis and Pyrgidis, Nikolaos and Kapoteli, Paraskeui and Zilotis, Filimon and Hatzichristou, Dimitrios},
  title = {The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial},
  journal = {The Journal of Sexual Medicine},
  year = {2024},
  volume = {21},
  number = {6},
  pages = {533--538},
  doi = {10.1093/jsxmed/qdae038}
}
Kostenlos starten →